Top Markets
Coin of the day
Theseus Pharmaceuticals, Inc. Theseus Pharmaceuticals, Inc.

Theseus Pharmaceuticals, Inc.

THRX
Rangering i aksjer #19949
Theseus Pharmaceuticals, Inc. is a biopharmaceutical company focused on... Theseus Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and bringing to market targeted treatments for cancer patients. Their leading investigational compound, THE-630, is a pan-KIT inhibitor undergoing Phase I clinical trials for treating gastrointestinal stromal tumors. The company is also advancing a fourth-generation EGFR inhibitor specifically designed to combat the C797S EGFR mutation, which confers resistance to initial or later-line osimertinib therapy in individuals with non-small cell lung cancer. All their research and development efforts aim to overcome drug resistance mutations within key driver oncogenes, which are mutated genes that promote cancer. Founded in 2017, the company operates out of Cambridge, Massachusetts.
Aksjekurs
$4.06
Sist synkronisert: 2024-02-23
Markedsverdi
$145.61M
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel Theseus Pharmaceuticals, Inc. (THRX)

Kategori

Inntekter for Theseus Pharmaceuticals, Inc. (THRX)
Inntekter i 2026 TTM: 0
Ifølge Theseus Pharmaceuticals, Inc. sine nyeste økonomiske rapporter er selskapets nåværende resultat 0. I 2026 hadde selskapet et resultat på 0, lik resultatet i 2026, som var 0. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Theseus Pharmaceuticals, Inc. fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
$5.27B -
US
$1.95B -
NL
$-3.09B -
US
$-4.02B -
AU
- -
CH